Rheumatoid Arthritis Key Opinion Leaders Module Elaborated by FirstWord
18 Sep 2012 • by Natalie Aster
KOLs have highlighted the need for less subjective tests which can be administered routinely to drive presentation and diagnosis. The potential use of biomarkers as tools to identify how well therapies will act on patients will help evaluate the clinical profile of the RA drugs reliably in different patient populations. Opinion leaders point out that we are moving towards biomarkers with reasonable specificity and sensitivity, which will help with diagnosis, treatment and prognosis of the disease. However, KOLs say it will be a number of years until they envisage a new biomarker on the market that will aid RA treatment decisions.
The report “Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module” by FirstWord examines key insights gained from the opinions of six key opinion leaders (KOLs) from North America and six KOLs from Europe. The results of the research and analysis identified the following major findings:
- Increasing uptake of the anti-TNF therapies drives historical market growth
- Development of more effective therapies is the primary unmet need
- Older anti-TNF therapies provide cornerstone of RA treatment
- Other mechanisms usually reserved for anti-TNF failures
- Tofacitinib will become the first oral therapy to enter market
- Biomarkers aid early diagnosis and improve treatment outcomes
Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module
Published: August, 2012
Price: US$ 4.995,00
More information can be found in the report “Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module” by FirstWord.
To order the report or ask for sample pages contact [email protected]